21 patents
Utility
Combination Therapy Involving Diaryl Macrocyclic Compounds
14 Dec 23
The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with an inhibitor of MAPK/ERK kinase-1 and -2 (MEK1 and MEK2; MAP2K1 and MAP2K2), such as trametinib.
Wei DENG, Dayong ZHAI, Laura RODON, Brion W. MURRAY, Jingrong J. CUI, Nathan V. LEE
Filed: 26 Apr 23
Utility
Chiral Diaryl Macrocycles and Uses Thereof
2 Nov 23
This disclosure relates to the use of certain diaryl macrocycle compounds, specifically (7S13R)-11-fluoro-7,13-di-methyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one in the treatment of disease in mammals.
Jingrong J. CUI, Yishan LI, Evan W. ROGERS, Dayong ZHAI, Wei DENG, Zhongdong HUANG
Filed: 15 Aug 22
Utility
Macrocycles for Use In Treating Disease
12 Oct 23
The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer.
Evan W. Rogers, Jane Ung, Vivian Nguyen, Dayong Zhai, Wei Deng, Jingrong J. Cui
Filed: 17 Mar 23
Utility
Diaryl Macrocycle Polymorph
21 Sep 23
This disclosure relates to polymorphs of (7S,13R)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10] benzoxatriazacyclotridecin-4(5H)-one that are useful in the treatment of disease, such as cancer, in mammals.
Jingrong J. Cui, Evan W. Rogers
Filed: 19 Sep 22
Utility
Polymorphs of a Macrocyclic Kinase Inhibitor
29 Dec 22
This disclosure relates to polymorphs of (3aR,11S,20aS)-7-fluoro-11-methyl-2,3,3a,12,13,20a-hexahydro-1H,5H-17,19-(metheno)cyclopenta[5,6][1,4]oxazino[3,4-i]pyrazolo[4,3-f]pyrido[3,2-l][1,4,8,10]oxatriazacyclotridecin-14(11H)-one that are useful in the treatment of disease, such as cancer, in mammals.
Wei DENG, Evan W. ROGERS, Yuelie LU, Han ZHANG, Jing LIU
Filed: 16 Jun 20
Utility
Macrocyclic Compounds and Uses Thereof
13 Oct 22
The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
Filed: 22 Feb 22
Utility
Macrocyclic Compounds for Treating Disease
29 Sep 22
The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
Filed: 14 Feb 22
Utility
Diaryl Macrocycles As Modulators of Protein Kinases
14 Apr 22
The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
Jingrong Jean CUI, Yishan Li, Evan W. Rogers, Dayong Zhai
Filed: 27 Sep 21
Utility
Macrocycles for Use In Treating Disease
12 Aug 21
The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer.
Evan W. Rogers, Jane Ung, Vivian Nguyen, Dayong Zhai, Wei Deng, Jingrong J. Cui
Filed: 26 Mar 21
Utility
Combination Therapy Involving Diaryl Macrocyclic Compounds
22 Jul 21
The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with a KRAS inhibitor, such as an inhibitor of KRAS G12C.
Wei DENG, Dayong ZHAI, Laura RODON, Brion W. MURRAY, Jingrong J. CUI
Filed: 25 Nov 20
Utility
Macrocyclic Compounds and Uses Thereof
15 Jul 21
The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
Filed: 25 Mar 21
Utility
Macrocycles for Use In Treating Disease
3 Jun 21
The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer.
Evan W. Rogers, Jane Ung, Vivian Nguyen, Dayong Zhai, Wei Deng, Jingrong J. Cui
Filed: 2 Dec 20
Utility
Combination Therapy Involving Diaryl Macrocyclic Compounds
27 May 21
The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with an inhibitor of MAPK/ERK kinase-1 and -2 (MEK1 and MEK2; MAP2K1 and MAP2K2), such as trametinib.
Wei DENG, Dayong ZHAI, Laura RODON, Brion W. MURRAY, Jingrong J. CUI, Nathan V. LEE
Filed: 25 Nov 20
Utility
Diaryl Macrocycle Polymorph
1 Apr 21
This disclosure relates to polymorphs of (7S,13R)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one that are useful in the treatment of disease, such as cancer, in mammals.
Jingrong J. Cui, Evan W. Rogers
Filed: 15 Oct 20
Utility
Macrocyclic Kinase Inhibitors and Their Use
25 Mar 21
The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
Evan W. ROGERS, Jane UNG, Han ZHANG, Jeffrey WHITTEN, Dayong ZHAI, Wei DENG, Jingrong Jean CUI
Filed: 18 Dec 18
Utility
Chiral Diaryl Macrocycles and Uses Thereof
4 Feb 21
This disclosure relates to the use of certain diaryl macrocycle compounds, specifically (7S13R)-11-fluoro-7,13-di-methyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one in the treatment of disease in mammals.
Jingrong J. CUI, Yishan LI, Evan W. ROGERS, Dayong ZHAI, Wei DENG, Zhongdong HUANG
Filed: 20 Aug 20
Utility
Macrocyclic Compounds for Treating Disease
16 Dec 20
The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
Filed: 4 May 20
Utility
Diaryl Macrocycles As Modulators of Protein Kinases
8 Jul 20
The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
Jingrong Jean Cui, Yishan Li, Evan W. Rogers, Dayong Zhai
Filed: 20 Feb 20
Utility
Macrocyclic Compounds for Treating Disease
17 Jun 20
The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
Filed: 29 Jan 20
Utility
Macrocyclic Compounds and Uses Thereof
20 May 20
The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
Jingrong Jean CUI, Evan W. ROGERS, Jane UNG, Jeffrey Whitten, Dayong Zhai, Wei DENG, Xin ZHANG, Zhongdong HUANG, Jing LIU, Han ZHANG
Filed: 25 Jul 18